Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Cell Therapeutics' PIXUVRI Gets Market Access In France - Quick Facts

RELATED NEWS
Trade CTIC now with 

Cell Therapeutics, Inc. (CTIC: Quote), Monday said its Pixuvri has been granted market access, by the Transparency Commission of the French National Health Authority. Pixuvri is to be used as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma or NHL.

Cell Therapeutics further said that the next and the final step in France's pharmaceutical reimbursement process is inclusion on the list of medicines approved for hospital use and subsequent publication in the Journal Officiel in France, which it intends to pursue.

The Transparency Commission said that the aggressive NHL is a serious disease and that there are no standard treatments for patients with this stage of disease.

"We are pleased to receive the CT's favorable opinion for reimbursement of PIXUVRI and look forward to bringing this new approved therapy to patients in France with aggressive NHL," said James Bianco, President and CEO.

Click here to receive FREE breaking news email alerts for CTI BioPharma Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks continue to show a lack of direction in mid-day trading on Tuesday following the long, holiday weekend. Even with the lackluster performance, the markets are largely holding on to the bulk of their recent gains. After reporting an unexpected drop in U.S. construction spending in the previous month, the Commerce Department released a report on Tuesday showing that construction spending rebounded by more than expected in the month of July. Activity in the U.S. manufacturing sector unexpectedly grew at an accelerated rate in the month of August, according to a report released by the Institute for Supply Management on Tuesday, with the index of activity in the sector climbing to a three-year high.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.